Clinical Research Directory

Inclusion Criteria: * SPECIFIC AIM 1A: Adult patients 18-85 years old * SPECIFIC AIM 1A INTERVENTION CLUSTERS: BE Risk Tool Score \> 0.087, indicating a higher risk for BE/esophageal adenocarcinoma (EAC). This will be run as a web-based application integrating data from several domains in the electronic health record (EPIC). Output score will range from 0-1. * SPECIFIC AIM 1A CONTROL CLUSTERS: Meeting American College of Gastroenterology (ACG) screening criteria (gastroesophageal reflux disease \[GERD\]+ \> 2 BE risk factors: Age ≥ 50 years, Male sex, Caucasian race, obesity \[body mass index (BMI) \> 30\], ever smoker, family history of BE/EAC) * SPECIFIC AIM 1B: A "low risk" BE risk tool score (\< 0.0897) Exclusion Criteria: * SPECIFIC AIM 1A: History of Barrett's esophagus or esophageal adenocarcinoma * SPECIFIC AIM 1A: Prior endoscopy in the last 10 years * SPECIFIC AIM 1A: Patients who are unable to consent * SPECIFIC AIM 1A: Patients with a current history of uninvestigated dysphagia * SPECIFIC AIM 1A: History of eosinophilic esophagitis, achalasia * SPECIFIC AIM 1A: Patients on oral anticoagulation including Coumadin, Warfarin unless discontinued for five days prior to the sponge procedure * SPECIFIC AIM 1A: Patients on antiplatelet agents including Clopidogrel, unless discontinued for five days prior to the sponge procedure * SPECIFIC AIM 1A: Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, unless discontinued for five days prior to the sponge procedure * SPECIFIC AIM 1A: Patients with a history of known varices or cirrhosis * SPECIFIC AIM 1A: Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma * SPECIFIC AIM 1A: Patients with congenital or acquired bleeding diatheses * SPECIFIC AIM 1A: Patients with a history of esophageal squamous dysplasia or esophageal squamous carcinoma * SPECIFIC AIM 1A: Patients with limited life expectancy (\< 2 years): per provider judgement * SPECIFIC AIM 1B: History of Barrett's esophagus or esophageal adenocarcinoma * SPECIFIC AIM 1B: Prior endoscopy in the last 10 years * SPECIFIC AIM 1B: Patients who are unable to consent * SPECIFIC AIM 1B: Patients with a current history of uninvestigated dysphagia * SPECIFIC AIM 1B: History of eosinophilic esophagitis, achalasia * SPECIFIC AIM 1B: Patients on oral anticoagulation including Coumadin, Warfarin unless discontinued for five days prior to procedure * SPECIFIC AIM 1B: Patients on antiplatelet agents including Clopidogrel, unless discontinued for five days prior to procedure * SPECIFIC AIM 1B: Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, unless discontinued for five days prior to procedure * SPECIFIC AIM 1B: Patients with a history of known varices or cirrhosis * SPECIFIC AIM 1B: Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma * SPECIFIC AIM 1B: Patients with congenital or acquired bleeding diatheses * SPECIFIC AIM 1B: Patients with a history of esophageal squamous dysplasia or esophageal squamous carcinoma * SPECIFIC AIM 1B: Patients with limited life expectancy (\< 2 years): per provider judgement